Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study.

Citation data:

Thorax, ISSN: 1468-3296, Vol: 72, Issue: 5, Page: 472-474

Publication Year:
2017
Usage 8
Abstract Views 8
Captures 26
Readers 26
Social Media 4
Tweets 4
Citations 2
Citation Indexes 2
PMID:
28130491
DOI:
10.1136/thoraxjnl-2016-209568
Author(s):
Podolanczuk, Anna J; Raghu, Ganesh; Tsai, Michael Y; Kawut, Steven M; Peterson, Eric; Sonti, Rajiv; Rabinowitz, Daniel; Johnson, Craig; Barr, R Graham; Hinckley Stukovsky, Karen; Hoffman, Eric A; Carr, J Jeffrey; Ahmed, Firas S; Jacobs, David R; Watson, Karol; Shea, Steven J; Lederer, David J Show More Hide
Publisher(s):
BMJ
Tags:
Medicine
Most Recent Tweet View All Tweets
article description
We investigated associations of plasma lipoproteins with subclinical interstitial lung disease (ILD) by measuring high attenuation areas (HAA: lung voxels between -600 and -250 Hounsfield units) in 6700 adults and serum MMP-7 and SP-A in 1216 adults age 45-84 without clinical cardiovascular disease in Multi-Ethnic Study of Atherosclerosis. In cross-sectional analyses, each SD decrement in high density lipoprotein cholesterol (HDL-C) was associated with a 2.12% HAA increment (95% CI 1.44% to 2.79%), a 3.53% MMP-7 increment (95% CI 0.93% to 6.07%) and a 6.37% SP-A increment (95% CI 1.35% to 11.13%), independent of demographics, smoking and inflammatory biomarkers. These findings support a novel hypothesis that HDL-C might influence subclinical lung injury and extracellular matrix remodelling.